| 05th week of 2016 patent applcation highlights part 9 |
| Patent application number | Title | Published |
|---|
| 20160030345 | Core Compositions - The present invention is directed to a process for adsorbing an active pharmaceutical ingredient onto a substrate, comprising the steps of (a) adding and mixing an inert adsorbent to a non-solid form comprising the active pharmaceutical ingredient, thereby forming a mixture; and (b) drying the mixture to form a solid crumbly material. | 2016-02-04 |
| 20160030346 | ENGINEERED AEROSOL PARTICLES, AND ASSOCIATED METHODS - An engineered aerosol particle for use in aerosol applications is provided. The engineered aerosol particle comprises a fabricated nanoparticle body member being non-spherical. The fabricated nanoparticle body member is configured to provide at least one of auto-rotation, tumbling, or lift when entrained in an airstream to thereby increase settling time of the fabricated nanoparticle body member. An associated method is also provided. | 2016-02-04 |
| 20160030347 | Stabilization Of Moisture-Sensitive Drugs - Described are stability-enhancing formulations of drugs that are sensitive to moisture. The formulations comprise co-granulates containing a moisture-sensitive drug and an excipient selected from fructose, xylitol, maltitol, and mixtures thereof. Also described are methods of producing a pharmaceutical tablet. The method comprises forming a blend of a moisture-sensitive drug and a first excipient selected from fructose, xylitol, maltitol, and mixtures thereof; spraying the blend with water to produce granules; drying and milling the granules; mixing a second excipient with the granules; and compressing into tablets. | 2016-02-04 |
| 20160030348 | VACCINATION COMPOSITION - The present invention is directed to vaccination composition comprising a particle comprising a polymer matrix incorporating an adjuvant and/or an antigen, to method of making them and use. Particularly, the present invention results in adjuvants and/or antigens, covalently entrapped in or coupled to polymer carriers or polymeric devices, such as micelles, nanoparticles, microspheres and other types of polymer devices for controlled release; the adjuvant and/or antigen are covalently bonded in or to the polymer carriers or polymeric devices. | 2016-02-04 |
| 20160030349 | NANOPARTICLES, METHODS OF PREPARATION, AND USES THEREOF - The present invention relates to core-shell nanoparticles, methods for their production, and their use, in particular as adjuvants. Generally, the nanoparticles of the invention comprise a solid core consisting of a biodegradable polymer and a shell of amphiphilic molecules disposed about said core. | 2016-02-04 |
| 20160030350 | PREPARATION OF COFFEE-BASED EXTRACTS AND POWDERS - Processes for preparing antioxidant-rich compositions, for example from coffee cherries, are disclosed. These processes can involve promptly contacting de-beaned coffee cherries with a preservative coating, and optionally storing under refrigerated conditions, prior to the preparation of an extract or powder. | 2016-02-04 |
| 20160030351 | SUSTAINED RELEASE MICROSPHERES AND METHOD OF PRODUCING SAME - A method of making a sustained release microsphere formulation, wherein the release rate of a bioactive ingredient is manipulated by controlling the crystallinity of said bioactive ingredient, includes the steps of combining the active ingredient and an encapsulating polymer in at least one solvent, or mixtures thereof, to form a dispersed phase and processing the dispersed phase without filtering, filtering the combined dispersed phase with a hydrophobic or a hydrophilic filter, or filtering the active ingredient and encapsulating polymer individually with a hydrophobic or hydrophilic filter before combining them to form the dispersed phase. The dispersed phase is then combined with a continuous phase to form the microsphere formulation. | 2016-02-04 |
| 20160030352 | DUAL DRUG DOSAGE FORMS WITH IMPROVED SEPARATION OF DRUGS - Drug tablets that include a prolonged-release core and an immediate-release layer or shell are prepared with a thin barrier layer of drug-free polymer between the prolonged-release and immediate-release portions of the tablet. The barrier layer is penetrable by gastrointestinal fluid, thereby providing full access of the gastrointestinal fluid to the prolonged-release core, but remains intact during the application of the immediate-release layer, substantially reducing or eliminating any penetration of the immediate-release drug into the prolonged-release portion. | 2016-02-04 |
| 20160030353 | SOLID PHARMACEUTICAL DOSAGE FORM OF DOLUTEGRAVIR - The present invention relates to a solid pharmaceutical dosage form comprising dolutegravir, a method of its preparation and its use in the treatment of an HIV infection. | 2016-02-04 |
| 20160030354 | COMBINATION TABLET WITH CHEWABLE OUTER LAYER - A pharmaceutical composition in the form of a combination tablet is described. The tablet has a rapidly absorbed component that enters the circulation by traversing the buccal mucosa, oral mucosa and combinations thereof, and a more slowly absorbed component that is swallowed. The therapeutic agent in the swallowed portion is absorbed across the gastric mucosa. The combination tablet may be modified, by varying the specific combinations of excipients, fillers, and the like to effect distinct release rates. In addition, the rapid and slow components may have identical or different therapeutic agents depending on the application to a specific medical condition. One embodiment of the combination tablet includes a prostaglandin inhibitor in the rapidly absorbed component in order to mitigate the side effects of immediate release niacin that is in the slow absorbing component. Such combination compositions will increase patient compliance with various dosing regimens due to the resulted decrease in the number of tablets that a patient would need to take on a daily basis. | 2016-02-04 |
| 20160030355 | OSMOTIC DRUG DELIVERY SYSTEM - An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent. | 2016-02-04 |
| 20160030356 | Stabilized Vitamin D Formulations - The present invention relates to stable solid formulations of vitamin D | 2016-02-04 |
| 20160030357 | COMPOSITION FOR MANUFACTURING ORALLY DISINTEGRATING DOSAGE FORM TO PROTECT COATING LAYER OF ACTIVE SUBSTANCE - The present invention relates to a method of manufacturing an orally disintegrating dosage form which masks a bitter or unpleasant taste. A composition including a ratio of excipients and a coated active substance prevents a coating layer on the active substance from being destroyed during manufacture. | 2016-02-04 |
| 20160030358 | Solid Dosage Form of Coated Bisphosphonate Particles - A solid dosage form comprises coated particles of bisphosphonate or a pharmaceutically acceptable analogue or derivative thereof. | 2016-02-04 |
| 20160030359 | Multi-Layer Hydrogel Capsules for Encapsulation of Cells and Cell Aggregates - Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject. | 2016-02-04 |
| 20160030360 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS - Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body. | 2016-02-04 |
| 20160030361 | CHOLESTOSOME VESICLES FOR INCORPORATION OF MOLECULES INTO CHYLOMICRONS - The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject. | 2016-02-04 |
| 20160030362 | SILICONE-CONTAINING ACRYLIC POLYMERS FOR TRANSDERMAL DRUG DELIVERY COMPOSITIONS - Described herein are silicone-containing acrylic polymers useful, for example, in transdermal drug delivery compositions, to methods of making and using them, to transdermal drug delivery compositions comprising them, and to methods of making and using such transdermal drug delivery compositions. The polymers are particular suitable for formulating amine drugs, such as amphetamine, methylphenidate, rivastigmine, paroxetine and clonidine. | 2016-02-04 |
| 20160030363 | Tincture For Infusing Resveratrol And Methods Of Use - Methods and formulations for infusing bioavailable resveratrol tinctures into food, beverage, cosmetic or drug products with minimal effect on the alcohol by volume of the product is provided. A resveratrol tincture includes an amount of trans-resveratrol mixed with a solvent of pure, or majority by weight, ethanol. The tincture is added to various food and beverages to make a bioavailable amount of trans-resveratrol to be absorbed and metabolized by the body providing demonstrated health benefits. | 2016-02-04 |
| 20160030364 | Therapeutic Compositions and Uses Thereof - This invention provides pharmaceutical compositions comprising compounds including 5-phenylpenta-2,4-dienoic acid, 3-methyl-3-butenyl caffeic acid, 1,1-dimethylallyl caffeic acid, pinobanksin-3-acetate, tectochrysin, pinostrobin chalcone, benzyl ferulate and benzyl isoferulate. Methods of using such compositions, in particular in the treatment or prevention of gastrointestinal cancers, and the resensitisation of gastrointestinal cancers to therapy are also provided. | 2016-02-04 |
| 20160030365 | PHARMACEUTICAL OR COSMETIC COMPOSITION SUITABLE TO PRESERVE EPITHELIAL STEM CELLS - The invention concerns the use of compounds of formula (I) R-N | 2016-02-04 |
| 20160030366 | COMPOSITIONS AND METHODS INCLUDING LEELAMINE AND ARACHIDONYL TRIFLUOROMETHYL KETONE RELATING TO TREATMENT OF CANCER - The present invention relates to compositions and methods for treatment of proliferative disease. In specific aspects, the present invention relates to compositions including (1R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-1-,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenemethanamine (leelamine) and arachidonyl trifluoromethyl ketone (ATK) in combination; methods for treatment of cancer including administration of leelamine and ATK in a subject in need thereof; and particularly methods for treatment of skin cancer including administration of leelamine and ATK in a subject in need thereof. | 2016-02-04 |
| 20160030367 | Methods and Compositions for Preventing Metastasis and for Improving the Survival Time - The invention relates to an AMPK activator (such as for instance metformin) for use in preventing metastasis in a patient suffering from a cancer, wherein said patient has a non-mutated p53 gene or lacks a mutant form of the p53 protein. The invention also relates to an AMPK activator for use in improving the survival time of a patient suffering from a cancer, wherein said patient has a non-mutated p53 gene or lacks a mutant form of the p53 protein. | 2016-02-04 |
| 20160030368 | SINUS ANESTHESIA KIT - An apparatus and method for anesthetizing various portions of a patient's nasal sinuses. For example, a kit can be provided that includes a first agent configured to modulate a rate of absorption of a subsequently-applied topical agent by one or more nasal structures. The kit also includes a first applicator configured to apply the first agent to a first portion of the one or more nasal structures. The kit also includes a second agent configured to anesthetize the first portion of the one or more nasal structures subsequent to application of the first agent and a second applicator configured to apply the second agent to the second portion of the one or more nasal structures. | 2016-02-04 |
| 20160030369 | FKBP52 TARGETING AGENT PHARMACEUTICAL COMPOSITIONS - Liposomes comprising an FKBP52 targeting agent (FTA) are disclosed. Pharmaceutical compositions comprising an FTA, a solvent, and a surfactant are disclosed. Pharmaceutical compositions comprising a cyclodextrin and/or a derivative thereof and an FTA are also disclosed. Method of detecting one or more compounds in a sample by liquid chromatography/tandem mass spectrometry (LC/MS/MS), methods of treating or preventing cancer, benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), prostatitis, enlarged prostate, or insulin-independent diabetes, and methods of inhibiting spermatogenesis or fertilized oocyte implantation in a mammal are also provided. | 2016-02-04 |
| 20160030370 | METHODS OF INTRAVENOUS ADMINISTRATION OF GLYBURIDE - The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 μg/hr and about 300 μg/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours. | 2016-02-04 |
| 20160030371 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS - This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. | 2016-02-04 |
| 20160030372 | MATERNAL CHELATION FOR EMBRYO, FETAL AND INFANT BENEFIT - This invention teaches the use of chelating agents to diagnose and treat metal toxins in a patient. Chelation agents are given to the mother for the benefit of the baby. Metal toxins such as lead, arsenic, mercury, tin, antimony, aluminum and others are known to cause miscarriages, birth defects, maldevelopment of the organs and tissues and maldevelopment of the brain. Chelation treatments of the mother can prevent these problems in the embryo, fetus and infant. Removal of lead and mercury and other toxins allows improved development of the offspring, both during the chelation and after the chelation is discontinued. Determining whether a mother who has just delivered a baby has elevated levels of heavy metals can also be used to identify the elevated metals of the mother as a possible cause of birth defects. | 2016-02-04 |
| 20160030373 | 2-AAA as a Biomarker and Therapeutic Agent for Diabetes - Methods for treating a glucose-related metabolic disorder (e.g., diabetes) comprising administration of 2-aminoadipic acid (2-AAA) to subjects in need thereof. Also described are methods for predicting a subject's risk of developing a glucose-related metabolic disorder, and to methods for selecting and monitoring a treatment for a glucose-related metabolic disorder (e.g., diabetes). | 2016-02-04 |
| 20160030374 | USE OF FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC INSUFFICIENCY, AND ASTHMA - According to a first aspect the invention relates to the use of fumaric acid derivatives selected from the group consisting of dialkyl fumarates, monoalkyl hydrogen fumarates, fumaric acid monoalkyl ester salts, fumaric acid monoamides, monoamido fumaric acid salts, fumaric acid diamides, monoalkyl monoamido fumarates, carbocyclic and oxacarbocyclic oligomers of these compounds and mixtures thereof for preparing a drug for the treatment or prevention of cardiac insufficiency, in particular left ventricular insufficiency, myocardial infarction and angina pectoris. | 2016-02-04 |
| 20160030375 | GLYCOGEN OR POLYSACCHARIDE STORAGE DISEASE TREATMENT METHOD - A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases. | 2016-02-04 |
| 20160030376 | Use of Genomic Testing and Ketogenic Compounds for Treatment of Reduced Cognitive Function - This invention relates to methods of using genotyping to select patients for treatment with compounds capable of elevating ketone body concentrations in amounts effective to treat reduced neuronal metabolism associated with reduced neuronal metabolism, for example Alzheimer's disease. | 2016-02-04 |
| 20160030377 | LIPID COMPOSITIONS FOR THE TREATMENT OF GASTRO-INTESTINAL DISORDERS AND THE PROMOTION OF INTESTINAL DEVELOPMENT AND MATURATION - The present invention provides a use of a lipid composition for the preparation of a nutritional, pharmaceutical or nutraceutical composition or a functional food, for the prevention and treatment of gastrointestinal diseases and disorders, and for promoting intestinal development, maturation, adaptation and differentiation. | 2016-02-04 |
| 20160030378 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS - The disclosure provides for a method for treating a fatty liver disease or disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic; has normal or substantially normal biliary tract function; or has non or early stage hepatocyte apoptosis; and administering a therapeutically effective amount of a pharmaceutical composition comprising EPAs. | 2016-02-04 |
| 20160030379 | Method for Treating Phytophotodermatitis - A method for treating phytophotodermatitis including the steps of applying an isothiocyanate functional surfactant to an area affected by phytophotodermatitis, wherein said isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. | 2016-02-04 |
| 20160030380 | Method for Treating Phytophotodermatitis - A method for treating phytophotodermatitis including the steps of applying an isothiocyanate functional surfactant to an area affected by phytophotodermatitis, wherein said isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. | 2016-02-04 |
| 20160030381 | Method for Treating Phytophotodermatitis - A method for treating phytophotodermatitis including the steps of applying an isothiocyanate functional surfactant to an area affected by phytophotodermatitis, wherein said isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. | 2016-02-04 |
| 20160030382 | Phenyl Carbamate Compounds for Use in Preventing or Treating Epilepsy or Epilepsy-Related Syndrome - The present invention provides a pharmaceutical composition for preventing and/or treating a epilepsy or epilepsy-related syndrome, for example an intractable epilepsy or its related syndrome such as drug-resistant epilepsy, comprising the phenyl carbamate compound as an active ingredient, and a use of the phenyl carbamate compound for preventing and/or treating epilepsy or epilepsy-related syndrome. | 2016-02-04 |
| 20160030383 | LOW-DOSE DOXEPIN FOR TREATMENT OF SLEEP DISORDERS IN ELDERLY PATIENTS - Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle. Also, the dosages described herein are safe tor elderly individuals. | 2016-02-04 |
| 20160030384 | 2-ACETYLNAPHTHO[2,3-B]FURAN -4,9-DIONE FOR USE ON TREATING CANCER - The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof. | 2016-02-04 |
| 20160030385 | COMBINATION THERAPY WITH SGLT-2 INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS - The present invention is directed to a pharmaceutical composition comprised of one or more SGLT-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class I obesity, class II obesity, class III obesity, visceral obesity and abdominal obesity, and metabolic syndrome. | 2016-02-04 |
| 20160030386 | PREVENTION OF ROSACEA INFLAMMATION - The disclosure demonstrates the role of mast cell stabilizers in treating rosacea. The disclosure also shows the role of mast cells, cathelicidin, serine protease and/or vitamin D3 in rosacea pathology and the use of antagonists and inhibitors thereof to treat rosacea. | 2016-02-04 |
| 20160030387 | CANNABINOID FORMULATIONS - The present invention provides stable, fast-acting liposomal and micelle formulations of cannabinoids that are suitable for pharmaceutical and nutraceutical applications. | 2016-02-04 |
| 20160030388 | DITERPENOID MEMBRANOLIDE COMPOUNDS HAVING ANTI-LEISHMANIA ACTIVITY AND USES THEREOF - In a screening program, the Antarctic sponge | 2016-02-04 |
| 20160030389 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING - The present invention relates to indole compounds and compositions and uses thereof, including uses of the indole compounds and compositions for the reduction or removal of localized fat deposits and/or tightening of skin and soft tissue laxity in subjects. The indole compounds can be employed, for example, in the cosmetic sector or for producing pharmaceutical products. | 2016-02-04 |
| 20160030390 | METHODS OF TREATING MUSCULAR DYSTROPHY - Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed. | 2016-02-04 |
| 20160030391 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION - This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A) in combination with memantine or a derivative or an analog thereof, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia or bipolar disorder, amyotrophic lateral sclerosis, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism, compulsive behavior, and substance addiction. | 2016-02-04 |
| 20160030392 | Treatment Or Prevention Of Hypotension And Shock - The present invention relates to a method for the prevention and treatment of hypotension and shock due to low peripheral resistance, comprising administering to a mammal in need thereof an effective amount of a certain imidazole derivative or pharmaceutically acceptable ester or salt thereof. In addition, the present invention relates to a method for the treatment of cardiopulmonary resuscitation, comprising administering to a mammal in need thereof an effective amount of a certain imidazole derivative or pharmaceutically acceptable ester or salt thereof. | 2016-02-04 |
| 20160030394 | Mazindol Combination In The Treatment Of Attention-Deficit/Hyperactivity - The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms. | 2016-02-04 |
| 20160030395 | SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES - Disclosed are substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-one compounds, pharmaceutical compositions comprising at least one such 4 substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-one compound processes for the preparation thereof, and the use thereof for inhibiting BET family of bromodomains and for treating disorders mediated thereby, such as certain cancers. | 2016-02-04 |
| 20160030396 | METHODS FOR TREATING RESPIRATORY DISEASES AND FORMULATIONS THEREFOR - Compounds, compositions, methods, and uses are described herein for the treatment of respiratory diseases, including cystic fibrosis. Inhalation formulations of macrolide antibiotics are also described herein. The treatment of bacterial infections continues to be an important endeavor of pharmaceutical research and development. The specter of bacterial resistance to currently available antibiotics is ever-present, and accordingly, new and improved compounds, pharmaceuticals formulations, treatment methods, and treatment protocols are needed. | 2016-02-04 |
| 20160030397 | COMPOSITIONS AND METHODS OF USING (R)-PRAMIPEXOLE - Pharmaceutical compositions of (R)-pramipexole and one or more secondary therapeutic agents such as, for example, dopamine agonists, dopaminergic agonists, COMT inhibitors, MOA inhibitors, excitatory amino acid antagonists, growth factors, neurotrophic factors, antioxidants, anti-inflammatory agents, immunomodulators, anti-glutamatergics, ion channel blockers, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, heat shock protein inducers/protein disaggregators and downregulators, monoamine oxidase type B (MOAB) inhibitors, multi-target agents, kinase inhibitors, Bcl inducers, histone deacetylase (HDAC) mediators, glial modulators, mitochondrial energy promoting agents, myostatin inhibitors, caspase inhibitors and combinations thereof or those related to mitochondrial dysfunction or increased oxidative stress are disclosed. | 2016-02-04 |
| 20160030398 | VETERINARY COMPOSITIONS FOR TREATING MASTITIS - The present invention relates to a veterinary composition for the prophylaxis and treatment of mastitis in mammals, preferably cows. The formulations of the present invention comprise two parts that are optionally administered to the animal as a blended formulation or two separate formulations. The first part is a seal formulation comprising a gel base and a non-toxic heavy metal salt in the base. The second part of the formulation is an oil-based product preferably containing an antibiotic in an oil-based formulation. The oil-based formulation may also optionally contain any other pharmaceutically active agent for the treatment or prophylaxis of disease in cattle. | 2016-02-04 |
| 20160030399 | METHOD OF REDUCING SOMNOLENCE IN PATIENTS TREATED WITH TIZANIDINE - An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution. | 2016-02-04 |
| 20160030400 | PHARMACEUTICAL DEPOT FOR N-{5-[(CYCLOPROPYLAMINO)CARBONYL]-2-METHYLPHENYL)-3-FLUORO-4-(PYRIDIN-2-Y- LMETHOXY)BENZAMIDE - A pharmaceutical depot comprising (i) N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide, or a pharmaceutically-acceptable salt thereof, as a pharmaceutical agent (PA) and (ii) a polymer which degrades to create an acidic microclimate, wherein the PA is released from the polymer upon polymer degradation. | 2016-02-04 |
| 20160030401 | USE OF MTOR INHIBITORS FOR PREVENTION OF INTESTINAL POLYP GROWTH AND CANCER - Disclosed are methods and compositions for the treatment or prevention of intestinal polyps or prevention of cancer in a patient who has been identified as being at risk for developing intestinal polyps or intestinal cancer. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (TOR). | 2016-02-04 |
| 20160030402 | SUSTAINED-RELEASE NANOPARTICLE COMPOSITIONS AND METHODS FOR USING THE SAME - The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an N-alkylacrylamide, a vinyl monomer, and a polyethylene glycol (PEG) conjugate and a method for using the same in the treatment or prevention of a disease or condition. | 2016-02-04 |
| 20160030403 | Novel Dosing Regimens of Celgosivir for the Treatment of Dengue - Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections. | 2016-02-04 |
| 20160030404 | Therapeutic Agents and Methods for the Treatment of DNA Repair Deficiency Disorders - The present invention provides compounds, compositions, its, and methods which are effective for mitigating, treating, or ameliorating a DNA repair-deficiency disorder or a symptom of a DNA repair-deficiency disorder. The compounds, compositions, kits, and methods are also effective for modulating a level or activity of a DNA repair enzyme or a level or activity of gene encoding a DNA repair enzyme. | 2016-02-04 |
| 20160030405 | 1-(5-TERT-BUTYL-2-PHENYL-2H-PYRAZOL-3-YL)-3-[2-FLUORO-4-(1-METHYL-2-OXO-2,- 3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-7-YLOXY)-PHENYL]-UREA AND RELATED COMPOUNDS AND THEIR USE IN THERAPY - The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (for convenience, collectively referred to herein as “IP compounds”), which, inter alia, are useful in the treatment of cancer, e.g., cancer characterised by (e.g., driven by) mutant RAS (“mutant RAS cancer”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions in the treatment of cancer, e.g., mutant RAS cancer. | 2016-02-04 |
| 20160030406 | CORRECTORS ACTING THROUGH MSD1 OF CFTR PROTEIN - The present disclosure provides methods for treating Cystic Fibrosis in a subject by administering to the subject a corrector agent capable of acting through MSD1 during the biosynthesis of CFTR protein. The disclosure also provides methods of screening for new corrector agents capable of acting through MSD1 during the biosynthesis of a CFTR protein. | 2016-02-04 |
| 20160030407 | Method of Treating Inflammatory Lung Disease - Pharmaceutical compositions comprising an isolated form of a compound of Formula I or IA (e.g., anatabine or S-(−)-anatabine) or a salt thereof can be used to treat disorders comprising an inflammatory component, including chronic, low-level inflammation. Compounds of Formula I also can be provided, for example, in other vehicles such as beverage products and consumer products such as lotions and creams. | 2016-02-04 |
| 20160030408 | MATERIALS AND METHODS FOR TREATING NEUROPATHIES AND RELATED DISORDERS INCLUDING THOSE INVOLVING A KEYSTONE NERVE - Methods, apparatus, compositions and kits for inhibiting a disorder in a human patient, including non-cerebral neurovascular disorder or muscular headache pain, or loss of motor or sensory function, sympathetic tone or range or fluidity of motion that affect a nerve pathway at more than one locus associated with the disorder to inhibit the disorder. Alternatively or in addition, neuropathy associated with a disorder is treatable by palpating to determine a Keystone nerve essential to the neuropathy, applying pressure to determine a point of maximum discomfort or trigger of increased symptoms to identify a Levin Sign as a locus of initial intervention, and intervening to treat the neuropathy at the location of the Levin Sign by administering a pharmaceutically active agent, internal implanted or external neuro stimulation affecting the nerve pathway to inhibit the neuropathy. | 2016-02-04 |
| 20160030409 | METHOD FOR RELIEVING CHRONIC PAIN - The method is for use in a part of a mammal having one or more tender points and comprises a dministering a fluid, by a needleless, pressure-based injector, to substantially all of the tender points in the part. The volume of the fluid that is administered to each of the tender points can be about 0.5 cc. The operating pressure of the injector can be about 150 psig. The fluid can be a local anesthetic such as ropivacaine. | 2016-02-04 |
| 20160030410 | AGENT FOR PROMOTING CORNEAL ENDOTHELIAL CELL ADHESION - The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium. | 2016-02-04 |
| 20160030411 | TREATMENT FOR CEREBRAL PALSY GAIT IMPAIRMENT - A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment secondary to cerebral palsy, or a gait impairment resultant side effect from anti-cancer and anti-seizure drugs. The administered methylphenidate simultaneously treats speech and gait or limb impairments secondary to a disease or disorder. | 2016-02-04 |
| 20160030412 | COMPOSITIONS AND METHODS FOR TREATMENT IN PARKINSON'S DISEASE PATIENTS - The invention provides dosage forms and methods for treating Parkinson's Disease, symptoms resulting from Parkinson's Disease, side effects resulting from treatment of Parkinson's Disease with other pharmaceutical agents, and reducing the progress of Parkinson's Disease. In various embodiments, the dosage forms and methods utilize nicotine and/or salts thereof for once daily administration resulting in four pulsatile releases following administration. | 2016-02-04 |
| 20160030413 | METHODS OF ACUTE RESTORATION OF VASCULAR COMPLIANCE - Disclosed herein is a compound for use in a composition applied to a blood vessel, wherein the compound softens and/or disrupts the crystalline matrix of calcified plaque, as well as acutely restoring the vascular compliance at the treatment site of the blood vessel, while maintaining luminal gain during angioplasty. Methods of treatment comprising applying the disclosed composition are also disclosed. Plaque-softening compounds are also disclosed. | 2016-02-04 |
| 20160030414 | BENZOQUINOLINE INHIBITORS OF VMAT 2 - The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof. | 2016-02-04 |
| 20160030415 | TREATMENT AND PROPHYLAXIS OF KIDNEY DISEASES - A method for treatment and/or prophylaxis of Kidney Diseases of Non-inflammatory etiology in mammals is described herein. The method comprises administering Hydroxychloroquine, its enantiomer or a pharmaceutically acceptable salt thereof or its combinations with at least one drug selected from the group of angiotensin receptor blockers and angiotensin converting enzyme inhibitors. More particularly, a method is provided for treatment and/or prophylaxis of Diabetic Kidney Disease in mammals, which comprises administering a therapeutically effective amount of Hydroxychloroquine, its enantiomer or a pharmaceutically acceptable salt thereof or its combinations with an angiotensin receptor blockers or an ACE inhibitors. Pharmaceutical compositions are provided for the above treatment. Provided is the use of Hydroxychloroquine, its enantiomer or a pharmaceutically acceptable salt thereof or its combinations with at least one drug selected from the group of angiotensin receptor blockers and ACE inhibitors, wherein in the treatment and/or prophylaxis of Kidney Diseases of Non-inflammatory etiology in mammals. | 2016-02-04 |
| 20160030416 | METHODS OF TREATING B2-BRADYKININ RECEPTOR MEDIATED ANGIOEDEMA - Methods of treating B | 2016-02-04 |
| 20160030417 | Pain Medicine Combination and Uses Thereof - Embodiments disclosed herein describe, amongst other things, dosage forms, compounds, compositions, pharmaceutical compositions that can be used in the treatment of, for example, pain and pain related disorders or to produce analgesia. | 2016-02-04 |
| 20160030418 | METHOD FOR DECREASING LOW DENSITY LIPID PROTEIN - The present invention relates to a method of decreasing cholesterol or low density lipid protein in a subject in need thereof comprising: administering to said subject a pharmaceuticaly effective amount of a composition comprising dextromethorphan. | 2016-02-04 |
| 20160030419 | ONCE-A-DAY OXYCODONE FORMULATIONS - The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C | 2016-02-04 |
| 20160030420 | COMPOSITIONS AND METHODS FOR INCREASING DEXTROMETHORPHAN PLASMA LEVELS AND RELATED PHARMACODYNAMIC EFFECTS - This disclosure relates to methods of increasing dextromethorphan plasma levels comprising co-administering hydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being in need of treatment with dextromethorphan. Dosage forms, drug delivery systems, and methods related to dextromethorphan and hydroxybupropion or a prodrug of bupropion are also disclosed. | 2016-02-04 |
| 20160030421 | COMPOSITIONS AND METHODS COMPRISING ERYTHROHYDROXYBUPROPION AND RELATED COMPOUNDS FOR IMPROVING THE EFFICACY OF DEXTROMETHORPHAN - This disclosure relates to methods of improving the efficacy of dextromethorphan, or providing beneficial pharmacokinetic effects to dextromethorphan, comprising co-administering erythrohydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan and erythrohydroxybupropion or a prodrug of erythrohydroxybupropion are also disclosed. | 2016-02-04 |
| 20160030422 | RBP4 ANTAGONISTS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE - A method for treating a disease characterized by excessive lipofuscin accumulation in the retina in a mammal afflicted therewith, comprising administering to the mammal an effective amount of a compound having the structure of any one of Formulas I-IV described herein, or a pharmaceutically acceptable salt thereof. | 2016-02-04 |
| 20160030423 | CARBOSTYRIL DERIVATIVES AND MOOD STABILIZERS FOR TREATING MOOD DISORDERS - The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-serotonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamazapine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, mania or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder. | 2016-02-04 |
| 20160030424 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE AND COMBINATION THERAPIES THEREOF - The present invention relates to compounds useful as inhibitors of ATR protein kinase and combination therapies thereof. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. | 2016-02-04 |
| 20160030425 | METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS - Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations. | 2016-02-04 |
| 20160030426 | HETEROARYL COMPOUNDS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful for treating a variety of diseases, disorders or conditions, associated with abnormal cellular responses triggered by protein kinase-mediated events. Compounds provided by this invention are also useful for the study of kinases in biological and pathological phenoma, the study of intracellular signal transduction pathways mediated by such kinases and the comparative evaluation of new kinase inhibitors. | 2016-02-04 |
| 20160030427 | METHODS FOR REDUCING THE RISK OF AN ADVERSE TERIFLUNOMIDE AND ROSUVASTATIN INTERACTION IN MULTIPLE SCLEROSIS PATIENTS - This invention relates to a method for managing the risk of an adverse interaction between teriflunomide and a substrate of breast cancer resistance protein (BCRP) and/or organic anion transporting polypeptide B1 and B3 (OATP1B1/B3). | 2016-02-04 |
| 20160030428 | PYRIMIDINEDIONE COMPOUNDS - Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease. | 2016-02-04 |
| 20160030429 | COMPOSITION AND METHOD FOR TREATING OR PREVENTING SKELETAL MUSCLE FIBROSIS - A compound in combination with a pharmaceutically acceptable carrier, the compound having a formula: wherein: R | 2016-02-04 |
| 20160030430 | TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS - Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis | 2016-02-04 |
| 20160030431 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE - The present invention provides compositions for reducing amyloid plaque burden associated with Alzheimer's disease and methods of using the same. | 2016-02-04 |
| 20160030432 | HYDROCHLORIDE SALT OF((1S,2S,4R)-4--2-HYDROXYCYCLOPENTYL) METHYL SULFAMATE - Disclosed is a compound of formula (I): | 2016-02-04 |
| 20160030433 | COMPANION DIAGNOSTIC FOR CDK4 INHIBITORS - The present invention relates to the use of one or more biomarkers to evaluate the likelihood that a CDK4 inhibitor would produce an anti-cancer effect in a subject. It is based, at least in part, on the discovery that cancer treatment with a CDK4 inhibitor is more effective where treated cancer cells undergo cellular senescence rather than a transient cell cycle arrest, where cellular senescence is associated with decreased MDM2 protein level. Accordingly, in non-limiting embodiments, the present invention provides for methods, compositions, and kits for a companion diagnostic for CDK4 inhibitors, and in particular, to the use of MDM2 expression as a biomarker for the likelihood that a cancer can be successfully treated by CDK4 inhibition. | 2016-02-04 |
| 20160030434 | THEOBROMINE COMPOSITIONS USEFUL FOR INCREASING FETAL WEIGHT GAIN AND ENHANCING BONE PROPERTIES - Compositions and methods for culturing cells with theobromine are provided, as well as cells derived thereby. Theobromine compositions for enhancing bone formation, increasing bone density, increasing interconnections of internal bone, increasing bone mass, treating cartilage and/or bone defects, increasing fetal birth weight, preventing tooth decay, remineralizing a tooth surface, treating dentine hypersensitivity, and application to a bone site to promote new bone growth at the site are also provided. | 2016-02-04 |
| 20160030435 | PHOSPHODIESTERASE INHIBITOR TREATMENT - Methods and compositions are disclosed for the treatment of taste and smell disorders. The compositions comprise phosphodiesterase inhibitors and are formulated for intranasal administration. | 2016-02-04 |
| 20160030436 | MOSAPRIDE SUSTAINED-RELEASE FORMULATION PROVIDING PHARMACOLOGICAL AND CLINICAL EFFECTS WITH ONCE-DAILY ADMINISTRATION - The formulation for oral administration of the present invention containing Mosapride or its salt is a double layer formulation consisting of a fast-release layer for rapid release of a drug and a sustained-release layer for slow release in order to simultaneously satisfy the rapid exhibition of pharmacological activities and sustained maintenance of pharmacological activities for 24 hours, wherein the high-viscosity hydroxypropyl methylcellulose (HPMC) and the low-viscosity HPMC are used in mixture such that the content of a high viscosity HPMC as a controlled-release matrix within the sustained-release layer has a higher content, thereby capable of controlling the dissolution rate in the regions having different pH values within the gastrointestinal tract and/or the retention time in the gastrointestinal tract. Additionally, the formulation of the present invention is a small-sized preparation with a total weight of 200 mg or less, preferably from 150 mg to 160 mg, thus capable of improving drug compliance of patients. | 2016-02-04 |
| 20160030437 | TAU AGGREGATION INHIBITOR - A tau aggregation inhibitor can sufficiently inhibit a tau protein from aggregating in cells. The inhibitor includes a 4-substituted catechol structure compound, having, at position 4 of its catechol ring, an electron-donating substituent R other than a hydrocarbon group, or a salt thereof. The 4-substituted catechol structure compound is preferably 4-aminocatechol or 1,2,4-benzenetriol. Examples of tauopathies to which this inhibitor is applicable include AD, Down's syndrome, frontotemporal dementia, cotricobasal degeneration (CBD) and progressive supranuclear palsy (PSP). | 2016-02-04 |
| 20160030438 | ANTI-TUMORAL COMPOSITION COMPRISING A PI3KBETA INHIBITOR AND A RAF INHIBITOR, TO OVERCOME CANCER CELLS RESISTANCE - The present invention concerns a combination of a PI3Kβ inhibitor with a RAF inhibitor for its use for the treatment of a patient resistant to at least one RAF inhibitor, a kit comprising the same, its pharmaceutical uses thereof and a method of monitoring the efficiency of said combination when administered to a patient. | 2016-02-04 |
| 20160030439 | METHODS FOR THE TREATMENT OF AUTOIMMUNE DISEASES - The present invention provides a method for inducing CD8 | 2016-02-04 |
| 20160030440 | ANTI-TUMORAL COMPOSITION COMPRISING A PI3KBETA-SELECTIVE INHIBITOR AND A PI3KALPHA-SELECTIVE INHIBITOR - The present invention concerns a combination of a PI3Kβ selective inhibitor with a PI3Kα selective inhibitor for use in the treatment of cancer. | 2016-02-04 |
| 20160030441 | NIACIN MIMETICS, AND METHODS OF USE THEREOF - Disclosed are 6-(morpholinoalkyl)-substituted pyridines, and pharmaceutically acceptable salts and prodrugs thereof, that are active against a range of mammalian therapeutic indications. | 2016-02-04 |
| 20160030442 | NOVEL COMPOUNDS - Compounds of formula (I) | 2016-02-04 |
| 20160030443 | METHODS AND COMPOSITIONS FOR MODULATING REGULATORY T CELL FUNCTION - Pharmaceutical compositions comprising a compound selected from the group consisting of Compound Nos. 1, 2, 3, 4, 5, 6, 7, 13, 22, 23, 24 and 25, as described in Table 1, and a pharmaceutically acceptable excipient. The pharmaceutical composition of the invention may further comprise an antigen, and/or an adjuvant. Also provided are methods of inhibiting a regulatory T (Treg) cell-mediated immune suppression, or more generally a method for enhancing immune response using a pharmaceutical composition comprising a ligand for human Toll-like receptor (TLR) 8 which activates the MyD88-IRAK4 signalling pathway. The present invention further provides a method of screening for an inhibitor of Treg cells' suppressive activity of host immune response using CD4 | 2016-02-04 |
| 20160030444 | THERAPEUTIC USE OF DIAMINOPHENOTHIAZINES - Described are methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimised pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects. | 2016-02-04 |
| 20160030445 | METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTIONAL MODULATORS - In one aspect, the invention relates to pharmaceutical compositions comprising agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof; and agents that inhibit the expression of p27 | 2016-02-04 |
